VOLPARA HEALTH TECHNOLOGIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.145 AUD | +0.44% |
|
+0.44% | +3.62% |
| 12:00am | Volpara Health Technologies Limited(ASX:VHT) dropped from S&P/ASX Emerging Companies Index | CI |
| May. 03 | Volpara to Delist After Court Approves Acquisition by Lunit | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 62% by 2026.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Most analysts recommend that the stock should be sold or reduced.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.62% | 193M | - | ||
| +5.01% | 32.88B | C | ||
| +16.74% | 7.84B | C- | ||
| +22.38% | 3.95B | B- | ||
| -17.98% | 3.11B | C- | ||
| -19.88% | 1.38B | B | ||
| -30.65% | 1.21B | - | ||
| +5.89% | 933M | C | ||
| -33.44% | 911M | - | ||
| -24.21% | 829M | - | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VHT Stock
- Ratings Volpara Health Technologies Limited